drugset
Drugs / kisspeptin 112-121
last change Mar 2026 re-read 2 minutes ago

kisspeptin 112-121

Peptide

Developed for
hypogonadotropic hypogonadism · functional hypothalamic amenorrhea · hyperprolactinemia · hypogonadism
Investigated by
Massachusetts General Hospital · Massachusetts General Hospital · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Trials 12 · a red edge is where a trial was stopped

today NCT07224490 · Ph 1 NCT07224438 · Ph 2 NCT05901467 · Ph 1 NCT05971849 · Ph 1 NCT05896293 · Ph 2 NCT05633966 · Ph 1 NCT04648969 · Ph 2 NCT02956447 · Ph 2 NCT01952782 · Ph 1 NCT01438034 · Ph 1 NCT01438073 · Ph 1 NCT00914823 · Ph 1
2009201020112012201320142015201620172018201920202021202220232024202520262027202820292030
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 18 trials
Phase 1 NCT07224490 Mar 2026 → May 2030 expected Orthocoronavirinae infectious disease, long COVID-19, neurodegenerative disease, reproductive system disorder Massachusetts General Hospital Recruiting No outcome recorded
Phase 1 NCT05901467 Oct 2023 → May 2024 reproductive system disorder Massachusetts General Hospital Terminated No outcome recorded
Phase 1 NCT05971849 Oct 2023 → Apr 2024 polycystic ovary syndrome, reproductive system disorder Massachusetts General Hospital Completed No outcome recorded
Phase 1 NCT05633966 Dec 2022 → Aug 2025 functional hypothalamic amenorrhea, hypogonadotropic hypogonadism Massachusetts General Hospital Completed No outcome recorded
Phase 1 NCT01952782 Apr 2014 → May 2016 hypogonadotropic hypogonadism Massachusetts General Hospital Completed No outcome recorded
Phase 1 NCT01438034 Jun 2013 → Sep 2019 Kallmann syndrome Massachusetts General Hospital Completed No outcome recorded
Phase 1 NCT01438073 Sep 2011 → Apr 2016 gonadal agenesis, hypogonadotropic hypogonadism Massachusetts General Hospital Completed No outcome recorded
Phase 1 NCT00914823 Jun 2009 → Oct 2021 Kallmann syndrome, hyperprolactinemia, polycystic ovary syndrome Massachusetts General Hospital Completed No outcome recorded
Phase 24 trials
Phase 2 NCT07224438 Dec 2025 → May 2030 expected functional hypothalamic amenorrhea, hypogonadotropic hypogonadism Massachusetts General Hospital Recruiting No outcome recorded
Phase 2 NCT05896293 Feb 2023 → May 2028 expected hypogonadotropic hypogonadism Massachusetts General Hospital Recruiting No outcome recorded
Phase 2 NCT04648969 May 2019 → Aug 2025 hypogonadotropic hypogonadism Massachusetts General Hospital Completed No outcome recorded
Phase 2 NCT02956447 Nov 2017 → Jun 2023 hyperprolactinemia, hypogonadism Massachusetts General Hospital Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 13 sources stand behind the page.

FieldValueCited text
Known as kisspeptin 112-121 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07224438 ↗
11

NCT02956447 ↗

NCT05633966 ↗

NCT00914823 ↗

NCT04648969 ↗

NCT05896293 ↗

NCT01438073 ↗

NCT01438034 ↗

NCT05971849 ↗

NCT01952782 ↗

NCT05901467 ↗

NCT07224490 ↗
Action Activate “The neuropeptide kisspeptin, which stimulates gonadotropin-releasing hormone (GnRH) release” PMID 32232399 ↗ Aug 2020
Modality Peptide “The neuropeptide kisspeptin, which stimulates gonadotropin-releasing hormone (GnRH) release” PMID 32232399 ↗ Aug 2020
Route Intravenous “One or more IV or SC doses of kisspeptin 112-121, and/or short infusion (up to 12 hours) of kisspeptin 112-121” NCT00914823 ↗
Route Subcutaneous “One or more IV or SC doses of kisspeptin 112-121, and/or short infusion (up to 12 hours) of kisspeptin 112-121” NCT00914823 ↗